Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BG-C9074 |
Synonyms | |
Therapy Description |
Limited information is currently available on BG-C9074, a putative antibody-drug conjugate (ADC) targeting VTCN1 (B7H4) (May 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BG-C9074 | BG C9074|BGC9074 | Limited information is currently available on BG-C9074, a putative antibody-drug conjugate (ADC) targeting VTCN1 (B7H4) (May 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06233942 | Phase I | BG-C9074 BG-C9074 + Tislelizumab | Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 1 |